TransMedics, a medical device company that provides a system for organ transplants, announced terms for its IPO on Monday.
The Andover, MA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, TransMedics would command a fully diluted market value of $331 million.
TransMedics was founded in 1998 and booked $13 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol TMDX. Morgan Stanley and J.P. Morgan are the joint bookrunners on the deal. It is expected to price during the week of April 29, 2019.
